XRP News: Buy $XDX Token Developed On XRP As Ripple Acquires Circle And Volatility Shares Launches XRPI Futures ETF
By GlobeNewswire Published on May 26, 2025, 02:13 IST
SYDNEY, May 25, 2025 (GLOBE NEWSWIRE) — With just 3 days left before the XenDex presale ends, investors are rushing to secure their $XDX tokens ahead of major exchange listings. The timing couldn't be better: Ripple's acquisition of Circle, the issuer of USDC, and the launch of the first XRPI Futures ETF by Volatility Shares have sent shockwaves across the crypto world, boosting confidence in XRP and all projects built on its ledger.
Buy $XDX Before Listing On Binance
As XRP's ecosystem surges with momentum, XenDex is emerging as the XRP Ledger's most powerful DeFi hub, and early supporters are locking in their positions before it's too late.
What is XenDex On XRP Blockchain?
XenDex is the first all-in-one decentralized exchange (DEX) built natively on the XRP Ledger (XRPL). The platform offers secure, fast, and low-fee trading, combined with advanced DeFi tools like AI copy trading, non-custodial lending & borrowing, and cross-chain swaps, all from a clean, intuitive dashboard built for mass adoption.
Features And Problems XenDex Aims To Solve on XRP Ledger?
While XRP boasts of unmatched speed and scalability, it has long lacked critical DeFi infrastructure. XenDex is solving this by introducing: AI Copy Trading – Automatically mimic trades from top-performing wallets, and minimize losses
– Automatically mimic trades from top-performing wallets, and minimize losses Lending & Borrowing – Lend or borrow crypto assets on XenDex without intermediaries
– Lend or borrow crypto assets on XenDex without intermediaries Cross-Chain Trading – Swap XRP with tokens across Ethereum, Solana, and BNB Chain
– Swap XRP with tokens across Ethereum, Solana, and BNB Chain DAO Governance – Let $XDX holders vote on upgrades and listings
Purchase $XDX At A low Price & Earn Rewards
Why Should I Buy $XDX?
Asides from making profits from potential pump upon listing on various exchanges, holding $XDX gives you: Voting rights over platform upgrades
Staking and liquidity rewards
Reduced trading, lending and borrowing fees
Access to exclusive platform features & airdrops
Where Can I Trade $XDX?
After presale, $XDX will be listed on: Binance, Gate.io, MEXC, BitMart, FirstLedger, MagneticX
Is XenDex A Legit Project On XRP?
Buy $XDX At Discount Price
Yes. XenDex is backed by experienced developers and is undergoing third-party smart contract audits. It's already integrated with top XRPL tools like Xaman, XRP Toolkit, and Gitbook.
How Do I Buy $XDX?
XenDex Presale Details Soft Cap: Reached
Reached Hard Cap: Almost Filled
Almost Filled Time Left: Only 3 Days Remaining
Join XenDex Community Below
Website: https://xendex.net
Presale: https://xendex.net/presale
Telegram: https://t.me/xendexcommunity
Twitter/X: https://x.com/xendex_xrp
Docs: https://xdxdocs.gitbook.io
Contact:Frank Richards
[email protected]
Disclaimer : This is a paid post provided by XenDex. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed.Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.
Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a9ccb925-132e-465c-a09e-9809d0414911
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
ibex to Present at Baird's 2025 Global Consumer, Technology & Services Conference
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- IBEX Limited (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and AI-powered customer engagement technology solutions, today announced that CEO Bob Dechant and CFO Taylor Greenwald will participate in Baird's 2025 Global Consumer, Technology & Services Conference in New York City. Dechant and Greenwald will host a 'Fireside Chat' on Tuesday, June 3, 2025, at 2 p.m. ET to speak about the company and answer questions. They will also participate in one-on-one investor meetings. About ibexibex delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage and retain valuable customers. Today, ibex operates a global CX delivery center model consisting of approximately 30 operations facilities around the world, while deploying next generation technology to drive superior customer experiences for many of the world's leading companies across retail, e-commerce, healthcare, fintech, utilities and logistics. ibex leverages its diverse global team of more than 31,000 employees together with industry-leading technology, including the AI-powered ibex Wave iX solutions suite, to manage nearly 175 million critical customer interactions, adding over $2.2B in lifetime customer revenue each year and driving a truly differentiated customer experience. To learn more, visit our website at and connect with us on LinkedIn. IR Contact: Michael Darwal, EVP, Investor Relations, ibex, Contact: Dan Burris, VP, Marketing and Communications, ibex, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Altai Announces Repositioning of Investment Portfolio to Maximize Liquidity
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Altai Resources Inc. (TSXV: ATI) ('Altai' or the 'Company') announced today that the Company has completed the repositioning of its Canadian investment portfolio (the 'Investment Portfolio') through the sale of all marketable securities and the subsequent reinvestment of those net cash proceeds into cash and cash equivalents (the 'Repositioning'), to maximize the liquidity of the Investment Portfolio and to eliminate any associated equity market risk. As a result of the Repositioning, the Company's Investment Portfolio is now comprised of cash and cash equivalents, with a total market value of approximately $3.9 million. Based on the Company's total issued and outstanding common shares of 56,033,552 as of May 30, 2025 (the 'Common Shares'), the market value of the Investment Portfolio per Common Share is approximately $0.07. ABOUT THE COMPANY Altai Resources Inc. is a Toronto, Ontario based resource company with a producing oil property in Alberta, an exploration gold property in Quebec, and a Canadian investment portfolio comprised of cash and cash equivalents. Additional information about the Company is available on SEDAR+ at and on the Company's website at For further information, please contact:Kursat Kacira, Chairman & CEO/PresidentT: (647) 282-8324, E: kursatkacira@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news in to access your portfolio
Yahoo
31 minutes ago
- Yahoo
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, or FLT3/IDH co-mutations – – Favorable safety and tolerability profile in heavily pre-treated patients: limited myelosuppression; no clinically meaningful QTc prolongation; 3% of patients discontinued due to treatment-related adverse events – – Potential first approval of a once-daily, oral menin inhibitor for treatment of adult patients with relapsed or refractory NPM1-mutated AML with Priority Review and a PDUFA target action date of November 30, 2025 – – Kura Oncology to host virtual investor event today at 7:30pm ET / 4:30pm PT – SAN DIEGO and TOKYO, June 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, 'Kura') and Kyowa Kirin Co., Ltd. (TSE: 4151, 'Kyowa Kirin') announced the presentation of positive pivotal results from the KOMET-001 Phase 2 registration-directed trial of ziftomenib, a once-daily, oral investigational menin inhibitor, in patients with relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leukemia (AML) in an oral session today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from May 30 - June 3, 2025. "We are delighted to announce positive pivotal data from the KOMET-001 trial in R/R NPM1-mutated AML patients treated with ziftomenib," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "NPM1 mutations are among the most common in AML, representing approximately 30% of cases, and there are no FDA-approved therapies specifically for this patient population. With these encouraging results and a PDUFA target action date of November 30, 2025, we and our partners at Kyowa Kirin look forward to supporting FDA with its review of the ziftomenib New Drug Application (NDA) and are well-positioned to meaningfully impact relapsed or refractory patients with NPM1 mutations.' "Relapsed or refractory NPM1-mutated AML is a highly challenging disease with a poor prognosis and an urgent need for new treatments," said Eunice Wang, M.D., Chief of Leukemia Service, Professor of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. "The promising results for ziftomenib in this heavily pretreated population are highly encouraging. Notably, the clinically meaningful minimal residual disease (MRD)-negative responses observed as well as the similar response rates seen regardless of prior therapies, including hematopoietic stem cell transplantation (HSCT) and venetoclax, hold great promise for the potential use of ziftomenib in patients with relapsed and refractory NPM1-mutated AML.' The KOMET-001 Phase 2 population included 92 adult patients with R/R NPM1-m AML. The median age was 69 (range: 33 to 84). Patients were heavily pretreated, with 33% having received three or more prior lines of therapy (median prior lines: 2) and 59% having been previously treated with venetoclax. A complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 23% (21/92) was observed among patients with R/R NPM1-m AML in the Phase 2 portion of the KOMET-001 trial. Among those 21 patients who achieved CR/CRh, 13 had a CR and 8 had a CRh. The median duration of CR/CRh responses was 3.7 months (95% CI: 1.9, not estimable (NE)) and the restricted mean duration of response was 4.3 months (95% CI: 3.1, 5.6) at the time of the data cutoff. MRD status was assessed in 19 of 21 patients who achieved CR/CRh, and 63% (12/19) of these patients were MRD-negative. Comparable CR/CRh rates were observed across pre-specified subgroups, regardless of prior HSCT, prior venetoclax or FLT3/IDH co-mutations. Additional patient benefit beyond CR/CRh was observed with a rate of transfusion conversion of 21% (17/82; 95% CI: 13-31) and a rate of maintenance of transfusion independence of 20% (2/10; 95% CI: 3-56). A median OS of 16.4 months (95% CI, 9.6–20.4) was observed for responders (patients who achieved CR, CRh, CRi/CRp, MLFS or PR) and a median overall survival (OS) of 3.5 months (95% CI, 2.5–4.0) was observed among non-responders. The safety population included 112 adult patients with R/R NPM1-m AML from the pooled Phase 1b and Phase 2 portions of the KOMET-001 trial. The safety profile observed with ziftomenib in this population was consistent with previously reported data. Treatment-related adverse events (TRAEs) led to treatment discontinuations in 3% of patients. TRAEs of Grade ≥3 which occurred in more than 10% of patients were limited to differentiation syndrome (DS, 13%), which was well managed by protocol-specified mitigation strategies and no Grade 4/5 treatment-related DS was observed. Although QTc prolongation (1 Gr2; 2 Gr3) was reported in three patients per investigator assessment, all three patients were on concomitant medications associated with QTc prolongation, two had electrolyte abnormalities and one had a prior diagnosis of atrial fibrillation. 'Beyond ziftomenib's clinical activity, we are highly encouraged by its consistent safety and tolerability profile,' said Mollie Leoni, MD, Chief Medical Officer of Kura Oncology. 'Notably, the low rate of myelosuppression, low discontinuation rate, lack of clinically significant QTc prolongation, absence of drug-drug interactions, and effective management of differentiation syndrome underscore ziftomenib's potentially favorable benefit-risk profile for patients with relapsed or refractory NPM1-mutated AML.' 'The data presented at ASCO strengthen our conviction that ziftomenib has potential to become a meaningful treatment option for patients with relapsed or refractory AML with NPM1 mutations — patients who often face limited treatment options and significant uncertainty regarding their prognosis,' said Takeyoshi Yamashita, Ph.D., Executive Vice President and Chief Medical Officer of Kyowa Kirin. 'Encouraged by the favorable safety, tolerability, and promising clinical activity observed thus far, Kyowa Kirin, in collaboration with Kura, is working with urgency and purpose to bring ziftomenib monotherapy to patients as swiftly and responsibly as possible.' Virtual Investor Event Kura will host a virtual investor event featuring company management and investigators from the KOMET-001 trial of ziftomenib in R/R NPM1-m AML at 7:30pm ET / 4:30pm PT on Monday, June 2, 2025. Those who would like to participate may access the live webcast here, or register in advance for the teleconference event can also be accessed on the Investors section of Kura's website at An archived replay will be available shortly after the conclusion of the live event. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the FDA for the treatment of R/R NPM1-m AML. In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in KOMET-001, a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-m AML, has been completed, and the companies announced submission of an NDA for ziftomenib for the treatment of adult patients with R/R NPM1-m AML in the first quarter of 2025. Kura and Kyowa Kirin are conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-m and KMT2A-rearranged AML. Ziftomenib is also being evaluated in a Phase1 dose-escalation trial (KOMET-015) in combination with imatinib for treatment of patients with advanced GIST. KO-2806, a next-generation farnesyl transferase inhibitor (FTI), is being evaluated in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn. About Kyowa Kirin Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, Kyowa Kirin has invested in drug discovery and biotechnology innovation for more than 70 years and is currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology and rare diseases. A shared commitment to Kyowa Kirin's values, to sustainable growth, and to making people smile unites Kyowa Kirin across the globe. You can learn more about the business of Kyowa Kirin at Kura Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of ziftomenib; interactions with the FDA relating to our NDA for ziftomenib; the anticipated timing of FDA approval of our NDA and the potential to benefit patients with R/R NPM1-m AML. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, the risk that the collaboration with Kyowa Kirin is unsuccessful, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words 'may,' 'will,' 'would,' 'could,' 'should,' 'believes,' 'estimates,' 'projects,' 'promise,' 'potential,' 'expects,' 'plans,' 'anticipates,' 'intends,' 'continues,' 'designed,' 'goal,' or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Kura Contacts Investors: Patti Bank Managing Director(415) Media:media@ Kyowa Kirin Contacts Investors: Ryohei Kawaiir@ Media, Global:Wataru Suzuki, media@ in to access your portfolio
